VIDEO: More biosimilars to hit market in 2023 for psoriasis treatment
Click Here to Manage Email Alerts
In this Healio exclusive video, Jashin J. Wu, MD, FAAD, of the University of Miami Miller School of Medicine, discusses his American Academy of Dermatology Annual Meeting presentation on biologics and biosimilars in psoriasis treatment.
Spesolimab was approved for the treatment of generalized pustular psoriasis flares, Wu said, and according to a study in The New England Journal of Medicine, patients on an IV dose were more likely to have a clearance of their pustules compared with placebo.
According to Wu, biosimilars have been on the market in Europe since about 2015; however, despite being approved in the United States for “many years,” the biosimilars will first be on the market this year. Wu spoke of nine more approved biosimilars that will be released later in 2023.
“Most of these are already approved, but they are not allowed to come on the market until later this year because of pending litigation and whatnot,” Wu said.
Reference:
- Wu JJ. Psoriasis and atopic dermatitis: Advances in comorbidities and therapy. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans.